Publications

ASH 2020 - Prophylactic Ruxolitinib for Cytokine Release Syndrome in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab
Geoffrey L. Uy, MD; Michael P. Rettig, Stephanie Christ, MS; PhD; Ibrahim Aldoss, MD; Michael Byrne, DO; Harry Erba, MD, PhD; Martha L. Arellano, MD; Matthew C Foster, MD; John E. Godwin, MD; Farhad Ravandi, MD; Peter H. Sayre, MD, PhD; Anjali S. Advani, MD; Matthew J. Wieduwilt, MD, PhD; Ashkan Emadi, MD, PhD; Laura Michaelis, MD; Patrick J. Stiff, MD; Martin Wermke, MD; Norbert Vey, MD, PhD; Patrice Chevalier, MD PhD; Emmanuel Gyan, MD, PhD; Christian Recher, MD PhD; Fabio Ciceri, MD; Matteo Giovanni Carrabba, MD; Stefania Paolini, MD; Antonio Curti, MD, PhD; GerwinA Huls, MD, PhD; Mojca Jongen-Lavrencic, MD, PhD; John Muth, MS; Teia Curtis, BA; Marybeth Collins, BS; Erin Fehr, BS; Kuo Guo, MSc; Jian Zhao, PhD; Kathy Tran, BS; Patrick Kaminker, PhD; Priyanka Patel, Pharm D.; Ouiam Bakkacha, MD; Kenneth Jacobs, MD; Maya Kostova, PhD; Jennifer Seiler, PhD, RAC; Bob Löwenberg, MD, PhD; Sergio Rutella, MD, PhD, FRCPath; Roland B. Walter, MD, PhD, MS; Ezio Bonvini, MD; Jan K Davidson-Moncada, MD, PhD; John F. DiPersio, MD, PhD

ASH 2020 - Microenvironmental Immune Senescence and Exhaustion in AML Associate with Response to Flotetuzumab
Jayakumar Vadakekolathu, Tung-On Yau, Sarah E. Church, Michael P. Rettig, Ibrahim Aldoss, Geoffrey L. Uy, Norbert Vey, Ashkan Emadi, Peter H. Sayre, Roland B. Walter, Matthew C. Foster, Martha L. Arellano, John E. Godwin, Matthew J. Wieduwilt, Michael Byrne, Laura Michaelis, Patrick J. Stiff, Matteo G. Carrabba, Patrice Chevallier, Emmanuel Gyan, Christian Recher, Anjali S. Advani, Martin Wermke, Harry P. Erba, Fabio Ciceri, Gerwin A. Huls, Mojca Jongen-Lavrencic, Max S. Topp, Farhad Ravandi, Stefania Paolini, Antonio Curti, John Muth, Patrick Kaminker, Bob Löwenberg, Ezio Bonvini, Ivana Gojo, Leo Luznik, John F. DiPersio, Jan K. Davidson-Moncada, Sergio Rutella

ASH 2020 - Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in AML
Jayakumar Vadakekolathu, Tung On Yau, Heidi Altmann, Sarah E. Church, Hanna Knaus, Mark D. Minden, Jan Davidson-Moncada, Sarah K. Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik, Sergio Rutella

ASH 2020 - TP53 Abnormalities - Response to Flotetuzumab in AML
Catherine Lai, Jayakumar Vadakekolathu, Stephen Reeder, Sarah E. Church, Carmen Ballesteros-Merino, Ibrahim Aldoss, Anjali S. Advani, John Godwin, Matthew J. Wieduwilt, Martha Arellano,Geoffrey Uy, FarhadRavandi, Matthew Foster, Emmanuel Gyan, Patrick Stiff, Norbert Vey, Ashkan Emadi, Matteo Carrabba, Peter Sayre, Roland Walter, Kathy Tran, Erin Timmeny, Michael Rettig, Patrick Kaminker, John Muth, Kuo Guo, Tung On Yau, Peter J.M. Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F. DiPersio, Jan K. Davidson-Moncada, Sergio Rutella

ASH 2020 - Flotetuzumab Upregulates MHC Class II Expression on AML
Joseph Rimando, MD; Michael Rettig, PhD; Matt Christopher, MD, PhD; Miriam Kim, MD; John Muth, MS; Jan K. Davidson‐Moncada, MD, PhD; John DiPersio, MD, PhD

ASH 2020 - Flotetuzumab as Salvage Therapy for PIF and ER AML
Ibrahim Aldoss, MD; Geoffrey L. Uy, MD; Norbert Vey, MD, PhD; Ashkan Emadi, MD, PhD; Peter H. Sayre, MD, PhD; Roland B. Walter, MD, PhD, MS; Matthew C Foster, MD; Martha L. Arellano, MD; John E. Godwin, MD; Matthew J. Wieduwilt, MD, PhD; Michael Byrne, DO; Laura Michaelis, MD; Patrick J. Stiff, MD; Matteo Giovanni Carrabba, MD; Patrice Chevallier, MD, PhD; Emmanuel Gyan, MD, PhD; Christian Recher MD, PhD; Anjali S. Advani, MD; Martin Wermke, MD; Harry Erba, MD, PhD; Fabio Ciceri, MD; GerwinA Huls, MD, PhD; MojcaJongen-Lavrencic, MD, PhD;Max S. Topp, MD, PhD; FarhadRavandi, MD; Stefania Paolini, MD; Antonio Curti, MD, PhD; Michael P. Rettig, PhD; John Muth, MS; TeiaCurtis, BA; Marybeth Collins, BS; Erin Fehr, BS; Kuo Guo, MSc; Jian Zhao, PhD; Kathy Tran, BS; Patrick Kaminker, PhD; Priyanka Patel, Pharm D.; OuiamBakkacha, MD; Kenneth Jacobs, MD; Maya Kostova, PhD; Jennifer Seiler, PhD, RAC; Bob Löwenberg, MD, PhD; Sergio Rutella, MD, PhD, FRCPath; Ezio Bonvini, MD; Jan K Davidson-Moncada, MD, PhD; John F. DiPersio, MD, PhD

BLOOD ADVANCES 2020 - TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in AMLML
Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, Sarah E. Church, Tressa Hood, Anbarasu Lourdusamy, Michael P. Rettig, Ibrahim Aldoss, Anjali S. Advani, John Godwin, Matthew J. Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A. Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J. M. Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F. DiPersio, Jan K. Davidson-Moncada, Sergio Rutella. Blood Advances (2020) 4 (20): 5011–5024.

BLOOD 2020 - Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
Geoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, Peter H Sayre, Matthew J Wieduwilt, Anjali S. Advani, John E Godwin, Martha L. Arellano, Kendra Sweet, Ashkan Emadi, Farhad Ravandi, Harry P. Erba, Michael Byrne, Laura C. Michaelis, Max S Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin Huls, Mojca Jongen-Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick Stiff, Kristen Pettit, Bob Löwenberg, Sarah Church, Erica Katherine Anderson, Jayakumar Vadakekolathu, Marianne T Santaguida, Michael P Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, MD, Kathy Tran, Patrick Kaminker, Maya Kostova, Dr, Ezio Bonvini, Roland B Walter, Jan Kenneth Davidson-Moncada, Sergio Rutella, John F DiPersio; doi.org/10.1182/blood.2020007732; BLOOD, September 2020.

AACR 2020 - TP53 Abnormalities Correlate with Immune Infiltration and are Associated with Response to Flotetuzumab, an Investigational Immunotherapy, in Acute Myeloid Leukemia
Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder,Sarah E. Church, Tressa Hood, John Muth, Heidi Altmann, Marilena Ciciarello,AntonioCurti, PeterJ.M. Valk, BobLöwenberg, Martin Bornhäuser, John F. DiPersio, Jan K. Davidson-Moncada, and Sergio Rutella

ASH 2019 - A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Andrew H. Wei, Chun Yew Fong, Pau Montesinos, Maria Calbacho, Jordi Sierra, Jaime Perez De Oteyza, Jacob M. Rowe, Ofir Wolach, Yishai Ofran, Yakir Moshe, Jichao Sun, Jan Baughman, Eileen McNulty, Ezio Bonvini, Jon M. Wigginton and Jan K Davidson-Moncada

ASH 2019 - Flotetuzumab: an Investigational CD123xCD3 Bispecific DART® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies is Associated with Response to Treatment in Primary Refractory AML Patients
John E. Godwin, Carmen Ballesteros-Merino, Nikhil Lonberg, Shawn M. Jensen, Tarsem Moudgil, Carlo B. Bifulco, Sarah E. Church, Thomas Smith, Michael Bailey, James Gowen-MacDonald, Sergio Rutella, Jon M. Wigginton, John Muth, Jan Davidson-Moncada, Bernard A. Fox

ASH 2019 - Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123 ×CD3 Bispecific DART® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Sergio Rutella, Jayakumar Vadakekolathu, Mark D. Minden, Tressa Hood, Sarah E. Church, Stephen Reeder, Heidi Altmann, Amy H. Sullivan, Elena J. Viboch, Tasleema Patel, Narmin Ibrahimova, Sarah E. Warren, Andrea Arruda, Yan Liang, Marc Schmitz, Alessandra Cesano, Peter J.M. Valk, Bob Löwenberg, A. Graham Pockley, Martin Bornhäuser, Sarah K. Tasian, Michael P. Rettig, Jan Davidson-Moncada, John F. DiPersio

ASH 2019 - Flotetuzumab, an Investigational CD123 x CD3 Bispecific DART® Protein, in Salvage Therapy for Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia Patients
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C Foster, David A Sallman, Kendra L. Sweet, David A. Rizzieri, Peter H. Sayre, Anjali S. Advani, Ashkan Emadi, Matthew J. Wieduwilt, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Tamara Moyo, Sarah E. Church, Michael P. Rettig, Martha L. Arellano, John E. Godwin, Bob Löwenberg, GerwinHuls, FarhadRavandi, John Muth, Kathy Tran, Ouiam Bakkacha, Kenneth Jacobs, MojcaJongen-Lavrencic, Erin Timmeny, Max S. Topp, Stefania Paolini, KuoGuo, Teia Curtis, Jian Zhao, Jayakumar Vadakekolathu, Jon M. Wigginton, Ezio Bonvini, Sergio Rutella, M Roland B. Walter, Jan K Davidson-Moncada, and John F. DiPersi

BLOOD 2016 - Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform
Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L and DiPersio JF Blood 2016 127:122-131

ASH 2018 - Biomarkers and Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific DART® Molecule for T-cell Redirected Therapy
Kenneth Jacobs, Cedric Viero, John Godwin, Jan Baughman, Jichao Sun, Kang Ying, John Muth, Shengyan Hong, Norbert Vey, Kendra L. Sweet, Geoffrey L. Uy, Farhad Ravandi, Matthew C Foster, David A. Rizzieri, Martha L. Arellano, Michael P. Rettig, Max S. Topp, Gerwin Huls, Helene Lelièvre, Stefania Paolini, Fabio Ciceri, Matteo Giovanni Carrabba, Bob Löwenberg, John F. DiPersio, Jon Wigginton1 and Jan K. Davidson-Moncada

ASH 2018 - Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 ×CD3 Bispecific DART® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Sergio Rutella, Sarah E. Church, Jayakumar Vadakekolathu, Elena Viboch, Amy H. Sullivan, Tressa Hood, Sarah E. Warren, Alessandra Cesano, Ross La Motte-Mohs, John Muth, Helene Lelièvre, Bob Löwenberg, John F. DiPersio and Jan K. Davidson-Moncada

ASH 2018 - Bone Marrow T Cell Changes by Multiplex IHC After Treatment with Flotetuzumab, a CD123 x CD3 Bispecific DART® Protein, in a Primary Refractory t-AML Patient
John E. Godwin, Carmen Ballesteros-Merino, Carlo B. Bifulco, Helene Lelièvre, Jon M. Wigginton, Jan Davidson-Moncada, Bernard A. Fox

ASH 2018 - Phase 1 Cohort Expansion of Flotetuzumab, a CD123 x CD3 Bispecific DART® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Geoffrey L. Uy, MD, Michael P Rettig, PhD, Norbert Vey, MD, John Godwin, MD, Matthew Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Max S. Topp, MD, Gerwin Huls, MD, PhD, Mojca Jongen-Lavrencic, MD, PhD, Giovanni Martinelli, MD, Stefania Paolini, MD, PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Kendra Sweet, MD, Farhad Ravandi, MBBS, Sarah E Church, PhD, Jayakumar Vadakekolathu, PhD, Sergio Rutella, MD, PhD, FRCPath, Jichao Sun, PhD, Kang Yang, Jan Baughman, MPH, Teia Curtis, PhD, Erin Timmeny, Kerri Cali, Kathy Tran, John Muth, MS, Ross La MotteMohs, PhD, Camille Poirot, Pharm.D., Athanasios Pallis, MD, Alessandra Cesano, MD, PhD, Ezio Bonvini, MD, Jon Wigginton, MD, Bob Löwenberg, MD, PhD, Jan K DavidsonMoncada, MD, PhD and John F DiPersio, MD, PhD

Keystone 2018 - Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART® Molecules for Redirected T-cell Killing
Ling Huang, Ross La-Motte Mohs, Chia-Ying Kao Lam, Liqin Liu, Thomas Kaufman, Gurunadh Chichili, Ralph Alderson, Kurt Stahl, Jennifer G. Brown, Paul Moore, Syd Johnson and Ezio Bonvini

ASH 2017 - Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies
Michael P Rettig, John Godwin, Norbert Vey, Bernard Fox, Carmen Ballesteros-Merino, Carlo B Bifulco, Daner Li, Daniel Primo, Joan Ballesteros, Jichao Sun, Helene Lelièvre, Jan Baughman, Ross La Motte-Mohs, John Muth, Paul Moore, Ezio Bonvini, Jon Wigginton, John F DiPersio and Jan Davidson-Moncada

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Chichili G, Huang L, Li H, Burke S, He L, Tang Q, Jin L, Gorlatov S, Ciccarone V, Chen F, Koenig S, Shannon M, Alderson R, Moore P, Johnson S, Bonvini E. Sci Transl Med 27 May 2015; Vol. 7, Issue 289, 289ra82.

Product Candidates

Vobramitamab Duocarmazine (B7-H3 ADC)

Lorigerlimab (PD-1 × CTLA-4)

Enoblituzumab (anti-B7-H3)

Tebotelimab (PD-1 × LAG-3)

MGC026 (B7-H3 ADC)

MGC028 (ADAM9 ADC)

Flotetuzumab (CD123 × CD3)

Partnered Products & Product Candidates

Margetuximab (anti-HER2)

Retifanlimab (anti-PD-1)

MGD024 (CD123 × CD3)

IMGC936 (ADAM9)

Technology Platforms

Fc Optimization Platform

DART® Platform

TRIDENT® Platform